Evidence map›Paper›PMID 41927787›Full record

ArticleCellular & molecular immunology2026

Persistent IFN-I signaling inhibits mitochondrial oxidative metabolism in CD8

Liang Cheng, Guangming Li, Fei Luo, Wenwen Bi, Mengmeng Lu, Na Liu, Qiuchen Zhao, Runpeng Han, Hongyu Wang, Hao Yang and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular & molecular immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Liang ChengLineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. liangcheng1984@aliyun.com.ORCID 0009-0002-0669-5037
Guangming LiLineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Fei LuoDepartment of Infectious Diseases, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, State Key Laboratory of Virology and Biosafety, Wuhan University, Wuhan, China.ORCID 0000-0001-8245-5583
Wenwen BiLineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Mengmeng LuDepartment of Infectious Diseases, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, State Key Laboratory of Virology and Biosafety, Wuhan University, Wuhan, China.
Na LiuDepartment of Infectious Diseases, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, State Key Laboratory of Virology and Biosafety, Wuhan University, Wuhan, China.ORCID 0009-0004-6342-844X
Qiuchen ZhaoDepartment of Infectious Diseases, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, State Key Laboratory of Virology and Biosafety, Wuhan University, Wuhan, China.
Runpeng HanDepartment of Infectious Diseases, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, State Key Laboratory of Virology and Biosafety, Wuhan University, Wuhan, China.ORCID 0000-0002-4646-6928
Hongyu WangDepartment of Infectious Diseases, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, State Key Laboratory of Virology and Biosafety, Wuhan University, Wuhan, China.
Hao YangDepartment of Infectious Diseases, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, State Key Laboratory of Virology and Biosafety, Wuhan University, Wuhan, China.
Jianping MaLineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Wenjia HuDepartment of Infectious Diseases, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, State Key Laboratory of Virology and Biosafety, Wuhan University, Wuhan, China.
Haisheng YuLineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-1757-1411
Wei HouState Key Laboratory of Virology and Biosafety, Institute of Medical Virology, School of Basic Medical Sciences, Wuhan University, Wuhan, China.ORCID 0000-0003-1439-455X
Yong XiongDepartment of Infectious Diseases, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, State Key Laboratory of Virology and Biosafety, Wuhan University, Wuhan, China.
Nilu GoonetillekeLineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
R Brad JonesDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Lishan SuLineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. lsu@ihv.umaryland.edu.ORCID 0000-0002-0350-5560

Funding

Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirsR01AI136990 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AMARA, RAMA RAO, BOSINGER, STEVEN EDWARD · 2018 to 2022
$4.2M
Impact of HIV on the Tumor MicroenvironmentR01CA228172 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAMANIA, BLOSSOM A, DITTMER, DIRK P · 2018 to 2022
$2.0M
Tumor-associated pDC (TApDC) in liver cancer with HIV infectionR01CA298839 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Lishan Su · 2025 to 2026
$1.3M
National Natural Science Foundation of China (National Science Foundation of China) 82071784NCI NIH HHS R01 CA228172NCI NIH HHS R01 CA298839NIAID NIH HHS R01 AI136990
6 · The paper itself

Abstract

Persistent type I interferon (IFN-I) signaling contributes to immune exhaustion and promotes HIV-1 persistence. While we and others have demonstrated that blocking IFN-I signaling in vivo restores anti-HIV-1 T-cell function and reduces viral reservoirs, the underlying mechanism remains unclear. Here, we showed that in humanized mice (hu-mice) and cells from people living with HIV-1 (PLWH), IFN-I signaling impaired mitochondrial activity in CD8

Indexed as

CD8-Positive T-LymphocytesHIV-1HIV InfectionsInterferon Type IMitochondriaSignal TransductionAnimalsDeoxyglucoseGlycolysisHumansMiceDeoxyglucoseInterferon Type I2-DGCD8+ T cellHIV-1Immunometabolic reprogrammingOxidative phosphorylationType I interferon

Identifiers

PMID41927787
PMCPMC13128924

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.